Association of amino acid variations in the NS5A and E2-PePHD region of hepatitis C virus 1b with hepatocellular carcinoma

Journal of Viral Hepatitis

Volumn 15, Issue 1, 2008, Pages 58-65

  Hung, C H ^a   Chen, C H ^a   Lee, C M ^a,b   Wu, C M ^a   Hu, T H ^a   Wang, J H ^a   Yen, Y H ^a   Lu, S N ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Hepatitis C; Hepatocellular carcinoma; Interferon sensitivity determining region; NS5A; PKR eIF2 phosphorylation homology domain

Indexed keywords

AMINO ACID; E2 PROTEIN; INITIATION FACTOR 2ALPHA; NONSTRUCTURAL PROTEIN 5A; PROTEIN KINASE R; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CODON; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HEPATITIS C VIRUS; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STATISTICAL SIGNIFICANCE; SUBSTITUTION LINE; VIRUS LOAD;

ADULT; AGED; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BINDING SITES; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; GENOTYPE; HEPACIVIRUS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PROTEIN STRUCTURE, TERTIARY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; TAIWAN; VIRAL ENVELOPE PROTEINS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 36949033130     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00892.x     Document Type: Article

References (43)

1. Alter MJ. Epidemiology of hepatitis C in the west. Semin Liver Dis 1995 15 : 5 14.
2. Seeff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The Natl Heart, Lung, Blood Inst Study Group. N Engl J Med 1992 327 : 1906 1911.
3. Poynard T, Bedossa P, Oplon P. for the OBSTIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Nature history of liver fibrous progression in patients with chronic hepatitis C. Lancet 1997 349 : 825 832.
4. Saito I, Miyamura T, Ohbayashi A et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990 87 : 6547 6549.
5. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001 34 : 730 739.
6. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002 5 (Suppl. 1 S47 S56.
7. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999 340 : 1228 1233.
8. Freeman AJ, Dore GJ, Law MG et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001 34 : 809 816.
9. Wiley TE, McCarthy M, Breidi L, Mc Carthy M, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998 28 : 805 809.
10. Soto B, Sanchez-Quijano A, Rodrigo L, Leal M, Lissen E. HIV infection modifies the natural history of chronic parenterally acquired heptitis C with an unusually rapid progression to cirrhosis. A multicenter study on 547 patients. J Hepatol 1997 26 : 1 5.
11. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005 41 : 82 87.
12. Hung CH, Kuo FY, Wang JH et al. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy. Antivir Ther 2006 11 : 483 489.
13. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984 4 : 136 146.
14. Schirmacher P, Rogler CE, Dienes HP. Current pathogenetic and molecular concepts in viral liver carcinogenesis. Virchows Arch B Cell Pathol Incl Mol Pathol 1993 63 : 71 89.
15. Ray RB, Lagging LM, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J Virol 1996 70 : 4438 4443.
16. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998 4 : 1065 1067.
17. Chung YL, Sheu ML, Yen SH. Hepatitis C virus NS5A as a potential viral Bcl-2 homologue interacts with Bax and inhibits apoptosis in hepatocellular carcinoma. Int J Cancer 2003 107 : 65 73.
18. Tan SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci U S A 1999 96 : 5533 5538.
19. Lan KH, Sheu ML, Hwang SJ et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene 2002 21 : 4801 4811.
20. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001 75 : 1401 1407.
21. Lee CM, Lu SN, Hung CH et al. Hepatitis C virus genotypes in southern Taiwan: prevalence and clinical Implications. Trans R Soc Trop Med Hyg 2006 100 : 767 774.
22. Ikeda K, Kobayashi M, Someya T et al. Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis. Intervirology 2002 45 : 71 78.
23. Reid AE, Koziel MJ, Aiza I et al. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Am J Gastroenterol 1999 94 : 1619 1626.
24. Enomoto N, Sakuma I, Asahina Y et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996 334 : 77 81.
25. Witherell GW, Beineke P. Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response. J Med Virol 2001 63 : 8 16.
26. Hung CH, Lee CM, Lu SN et al. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. J Viral Hepat 2003 10 : 87 94.
27. Cuddihy AR, Wong AH, Tam NW, Li S, Koromilas AE. The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. Oncogene 1999 18 : 2690 2702.
28. Gale MJ Jr., Korth MJ, Tang NM et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997 230 : 217 227.
29. Sen GC, Ransohoff RM. Interferon-induced antiviral actions and their regulation. Adv Virus Res 1993 42 : 57 102.
30. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999 285 : 107 110.
31. Gimenez-Barcons M, Franco S, Suarez Y et al. High amino acid variability within the NS5A of hepatitis C virus (HCV) is associated with hepatocellular carcinoma in patients with HCV-1b-related cirrhosis. Hepatology 2001 34 : 158 167.
32. De Mitri MS, Morsica G, Cassini R et al. Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. J Hepatol 2002 36 : 116 122.
33. Bagaglio S, De Mitri MS, Lodrini S et al. Mutations in the E2-PePHD region of hepatitis C virus type 1b in patients with hepatocellular carcinoma. J Viral Hepat 2005 12 : 243 250.
34. Polyak SJ, Nousbaum JB, Larson AM, Cotler S, Carithers RL Jr., Gretch DR. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. J Infect Dis 2000 182 : 397 404.
35. Watanabe H, Enomoto N, Nagayama K et al. Number and position of mutations in the interferon (IFN) sensitivitydetermining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 2001 183 : 1195 1203.
36. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. J Viral Hepat 2006 13 : 582 590.
37. Adinolfi LE, Andreana A, Utili R, Zampino R, Ragone E, Ruggiero G. HCV RNA levels in serum, liver and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol 1998 93 : 2162 2166.
38. Coelho-Little E, Jeffers LJ, Bartholomew M, Reddy KR, Schiff ER, Dailey PJ. Correlation of HCV-RNA levels in serum and liver of patients with chronic hepatitis C. J Hepatol 1995 22 : 248 249.
39. Gretch D, Corey L, Wilson J et al. Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994 169 : 1219 1225.
40. Kao JH, Lai MY, Chen PJ, Hwang LH, Chen DS. Serum hepatitis C virus titers in the progression of type C chronic liver disease. With special emphasis on patients with type 1b infection. J Clin Gastroenterol 1996 23 : 280 283.
41. Franco S, Gimenez-Barcons M, Puig-Basagoiti F et al. Characterization and evolution of NS5A quasispecies of hepatitis C virus genotype 1b in patients with different stages of liver disease. J Med Virol 2003 71 : 195 204.
42. Fan W, Zhu W, Wei L et al. Nonstructural 5A gene variability of hepatitis C virus (HCV) during a 10-year follow up. J Gastroenterol 2005 40 : 43 51.
43. Ruster B, Zeuzem S, Krump-Konvalinkova V et al. Comparative sequence analysis of the core- and NS5-region of hepatitis C virus from tumor and adjacent non-tumor tissue. J Med Virol 2001 63 : 128 134.